184 related articles for article (PubMed ID: 17986535)
1. What can we do to preserve the peritoneum?
Krediet RT; Zweers MM; van Westrhenen R; Ho-dac-Pannekeet MM; Struijk DG
Perit Dial Int; 2003 Dec; 23 Suppl 2():S14-9. PubMed ID: 17986535
[TBL] [Abstract][Full Text] [Related]
2. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
3. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
Tomo T
Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
[TBL] [Abstract][Full Text] [Related]
5. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
6. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
7. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats.
Musi B; Braide M; Carlsson O; Wieslander A; Albrektsson A; Ketteler M; Westenfeld R; Floege J; Rippe B
Perit Dial Int; 2004; 24(1):37-47. PubMed ID: 15104335
[TBL] [Abstract][Full Text] [Related]
8. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
Haag-Weber M
Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
[TBL] [Abstract][Full Text] [Related]
9. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
10. A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution.
van Westrhenen R; Zweers MM; Kunne C; de Waart DR; van der Wal AC; Krediet RT
Perit Dial Int; 2008; 28(5):487-96. PubMed ID: 18708542
[TBL] [Abstract][Full Text] [Related]
11. Experimental study on long-term exposure to a biocompatible, hypertonic, pyruvate-buffered dialysis solution.
van Westrhenen R; Vlijm A; Hiralall JK; Krediet RT
Perit Dial Int; 2008 Nov; 28 Suppl 5():S43-7. PubMed ID: 19008540
[TBL] [Abstract][Full Text] [Related]
12. Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?
Krediet RT; Zweers MM; van Westrhenen R; Zegwaard A; Struijk DG
NDT Plus; 2008 Oct; 1(Suppl 4):iv56-iv62. PubMed ID: 25983988
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
[TBL] [Abstract][Full Text] [Related]
14. Recent concepts in the molecular biology of the peritoneal membrane - implications for more biocompatible dialysis solutions.
Mortier S; De Vriese AS; Lameire N
Blood Purif; 2003; 21(1):14-23. PubMed ID: 12566656
[TBL] [Abstract][Full Text] [Related]
15. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
16. Studying the effects of new peritoneal dialysis solutions on the peritoneum.
Chan TM; Yung S
Perit Dial Int; 2007 Jun; 27 Suppl 2():S87-93. PubMed ID: 17556337
[TBL] [Abstract][Full Text] [Related]
17. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation.
Park MS; Kim JK; Holmes C; Weiss MF
Perit Dial Int; 2000; 20 Suppl 5():S33-8. PubMed ID: 11229610
[TBL] [Abstract][Full Text] [Related]
18. Protecting the peritoneal membrane in dialyzed patients.
Grzegorzewska AE
Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions.
Cooker LA; Luneburg P; Holmes CJ; Jones S; Topley N;
Perit Dial Int; 2001; 21 Suppl 3():S102-7. PubMed ID: 11887802
[TBL] [Abstract][Full Text] [Related]
20. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
